Arthur He
Stock Analyst at HC Wainwright & Co.
(4.58)
# 321
Out of 5,182 analysts
53
Total ratings
60.71%
Success rate
39.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JBIO Jade Biosciences | Maintains: Buy | $35 → $45 | $26.85 | +67.60% | 3 | Apr 27, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $165 → $185 | $86.74 | +113.29% | 7 | Apr 20, 2026 | |
| SLDB Solid Biosciences | Reiterates: Buy | $20 | $7.50 | +166.67% | 11 | Mar 23, 2026 | |
| VERA Vera Therapeutics | Maintains: Buy | $90 → $110 | $37.28 | +195.06% | 4 | Mar 2, 2026 | |
| ADAG Adagene | Maintains: Buy | $8 → $7 | $3.56 | +96.63% | 11 | Aug 15, 2025 | |
| AUPH Aurinia Pharmaceuticals | Assumes: Buy | $17 | $16.37 | +3.85% | 1 | Jul 30, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.67 | - | 8 | May 20, 2025 | |
| BCAB BioAtla | Reiterates: Neutral | n/a | $4.51 | - | 8 | Mar 31, 2025 |
Jade Biosciences
Apr 27, 2026
Maintains: Buy
Price Target: $35 → $45
Current: $26.85
Upside: +67.60%
Nektar Therapeutics
Apr 20, 2026
Maintains: Buy
Price Target: $165 → $185
Current: $86.74
Upside: +113.29%
Solid Biosciences
Mar 23, 2026
Reiterates: Buy
Price Target: $20
Current: $7.50
Upside: +166.67%
Vera Therapeutics
Mar 2, 2026
Maintains: Buy
Price Target: $90 → $110
Current: $37.28
Upside: +195.06%
Adagene
Aug 15, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.56
Upside: +96.63%
Aurinia Pharmaceuticals
Jul 30, 2025
Assumes: Buy
Price Target: $17
Current: $16.37
Upside: +3.85%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.67
Upside: -
BioAtla
Mar 31, 2025
Reiterates: Neutral
Price Target: n/a
Current: $4.51
Upside: -